Trial Profile
Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 09 Nov 2015
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- 09 Nov 2015 New trial record